Meeting
2022 ASCO Annual Meeting
Type of endocrine therapy and DFS in patients with early HER2+/HR+ BC: Analysis from the phase III randomized ShortHER trial.
Authors
Maria Vittoria Dieci
University of Padova, Veneto Institute of Oncology IOV-IRCCS, Padua, Italy
Maria Vittoria Dieci , Giancarlo Bisagni , Alba Ariela Brandes , Antonio Frassoldati , Roberto Vicini , Sara Balduzzi , Roberto D'Amico , Pier Franco Conte , Valentina Guarneri
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Poster Session
Session Title
Breast Cancer—Local/Regional/Adjuvant
Track
Breast Cancer
Sub Track
Adjuvant Therapy
Clinical Trial Registration Number
NCT00629278
Citation
J Clin Oncol 40, 2022 (suppl 16; abstr 547)
DOI
10.1200/JCO.2022.40.16_suppl.547
Abstract #
547
Poster Bd #
319
Abstract Disclosures
Similar Posters
Poster
2022 ASCO Annual Meeting
Estradiol (E2) levels in premenopausal women with hormone receptor-positive (HR+) breast cancer (BC) on ovarian function suppression (OFS) with gonadotropin-releasing hormone agonists (GnRHa).
First Author: Megan Elizabeth Tesch
Poster
2023 ASCO Annual Meeting
Influence of hormone therapy timing intake on disease free survival (DFS) for patients with high-risk early breast cancer: Results of the UCBG-UNIRAD phase III randomized trial.
First Author: Sylvie Giacchetti
Poster
2019 ASCO Annual Meeting
In-depth gene expression analysis of premenopausal patients with HR+/HER2− advanced breast cancer (ABC) treated with ribociclib-containing therapy in the Phase III MONALEESA-7 trial.
First Author: Yen-Shen Lu
Poster
2017 ASCO Annual Meeting
Phase 3 randomized study of adjuvant anastrozole (A), exemestane (E), or letrozole (L) with or without tamoxifen (T) in postmenopausal women with hormone-responsive (HR) breast cancer: The FATA-GIM3 trial.
First Author: Francesco Perrone